A common UCP2 promoter polymorphism -866G/A has been shown to increase transcriptional activity by allowing for easier binding of the pancreatic transcription factor PAX6, increasing the risk of glucose dysregulation and type II diabetes in several human populations (25–29). This evidence concerns the gene UCP2 and type 2 diabetes mellitus.